SRPT•businesswire•
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Summary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Financial Update* (preliminary and unaudited) Total net product revenu
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 12, 2026 by businesswire